Efficacy of Rivaroxaban

Rivaroxabanis an anticoagulant that binds directly to factorXa. Thereafter, it effectively blocks the coagulation cascade and prevents the formation of blood clots. Rivaroxaban is a unique anticoagulant for two possible reasons. First, it does not involve antithrombin III (ATI III) to exert its anticoagulant effect. Second, it is an oral drug, whereas the widely used unfractionated heparin and low molecular weight heparin are only for parenteral administration.

Although activated partial thromboplastin time (aPTT) and HepTest (a test for detecting low molecular weight heparin) are prolonged in a dose-dependent manner, neither test is recommended for assessing the pharmacodynamic effects of rivaroxaban. Although affected by rivaroxaban, monitoring of anti-Xa activity and inhibition of anti-Xa activity are not recommended. Approximately 2/3 of rivaroxaban is excreted into the urine through active renal tubular secretion, of which approximately 36% is unchanged drug and 30% is inactive metabolites. The remaining 1/3 of the administered dose is excreted in the feces, of which 7% is the unchanged drug form and 21% is inactive metabolites.

RivaroxabanThe original drug is already on the market in China and can be found under Class B medical insurance. SpecificationsThe price of 10mg*5 tablets is around RMB 100. This drug may be sold in domestic pharmacies or hospitals. The Turkish version of rivaroxabanoriginal drug marketed overseas, specifications10mg*10 tablets, is priced around RMB 170 (the price may fluctuate due to exchange rates). The ingredients of the original rivaroxaban drug sold domestically and abroad are basically the same. Currently, there are no generic drugs produced in other countries on the market overseas.